Class / Patent application number | Description | Number of patent applications / Date published |
424900340 | Polypeptide attached to or complexed with the agent (e.g., protein, antibody, etc.) | 84 |
20080213190 | Selective Alfavbetas Receptor Peptide Antagonist for Therapeutic and Diagnostic Applications - The present invention is related to new peptide antagonists of α | 09-04-2008 |
20090041671 | PROTEIN CAGES FOR THE DELIVERY OF MEDICAL IMAGING AND THERAPEUTIC AGENTS - The present invention is directed to novel compositions and methods utilizing delivery agents comprising protein cages, medical imaging agents and therapeutic agents. | 02-12-2009 |
20090053141 | COMPOSITIONS AND METHODS FOR MAGNETIC RESONANCE IMAGING CONTRAST AGENTS - The present application provides for compositions and methods of creating and applying contrast agents that find use in magnetic resonance imaging (MRI). In particular, contrast agents that comprise monodisperse, protein polymer backbones capable of chelating multiple paramagnetic ions resulting in high relaxivity for use in enhancing MRI signal intensity. | 02-26-2009 |
20090068115 | Amine Functionalized Superparamagnetic Nanoparticles for the Synthesis of Bioconjugates and Uses Therefor - Amine functionalized magnetic nanoparticle compositions and processes for synthesizing the same are described. The process consists of obtaining a carboxylated polymer in substantially pure form, which is used to prepare a substantially size homogeneous, polymer coated carboxyl, functionalized magnetic nanoparticle. The carboxyl groups are converted to reactive primary amino groups by the use of a water-soluble carbodiimide followed by reaction of a large excess of a diamine. The amine-terminated nanoparticles are then reacted with bifunctional crosslinking agents and with various biomolecules to make nanoparticles for in vitro assays, cell sorting applications and target specific MR contrast agents. | 03-12-2009 |
20090087382 | CONTRAST AGENTS AND METHODS FOR PREPARING CONTRAST AGENTS - Contrast agents comprising a scaffold protein having at least one operative integrated metal ion binding site. | 04-02-2009 |
20090092555 | Octameric Protein For Use In Bionanotechnology Applications - The present invention relates to purified multimeric proteins, comprising PlyCB monomers or functional fragments or variants thereof, which self-assemble into a ring like structure. The present invention also encompasses such multimeric proteins that comprise an integrin-binding sequence. The present invention further discloses contrast reagents, implant coatings, bone implants, and complexes for use in bionanotechnology applications, each of which comprise such multimeric proteins. | 04-09-2009 |
20090162290 | METHOD FOR THE SYNTHESIS OF PENTA-PENDANT ENANTIOMER-PURE CHELATORS AND PROCESS FOR THERAPEUTICALLY ACTIVE BIOCONJUGATES PREPARATION BY A COVALENT BINDING THEREOF - The present invention provides a method for synthesis and binding methods of pentapendant enantiomer-pure chelators of formula (VII) wherein R | 06-25-2009 |
20090162291 | MAGNETIC RESONANCE CONTRAST MEDIUM USING POLYETHYLENE GLYCOL AND MAGNETIC RESONANCE IMAGE PICK-UP METHOD - An object of the invention is to provide a technique that is safe and quantitative, and is capable of continuously acquiring a magnetic resonance image with a short repetition time. | 06-25-2009 |
20090214438 | METHODS AND COMPOSITIONS FOR THE PREPARATION AND USE OF TOXIN CONJUGATES - The present invention relates to methods for the preparation of toxin conjugates that are useful in vaccination and other therapies and diagnostics. In particular, methods are provided that involve a [3+2] cycloaddition between a first reactive unsaturated group on a toxin moiety and a second reactive unsaturated group on a bioactive moiety. Also provided are conjugates that are formed through this conjugation method, pharmaceutical compositions comprising these conjugates, and methods of using these pharmaceutical compositions for the treatment or diagnostic of antigen-related conditions, including tumors and infections. | 08-27-2009 |
20090220432 | Imaging agents and methods of using same for detecting multidrug resistance in cancer - Compounds and methods of using such compounds in the imaging and detection of multidrug resistance cancer in a subject are provided. In particular, novel imaging agents are provided which are suitable for the detection and imaging of a multidrug resistance phenotype in cancer cells and/or tissues using non-invasive medical imaging modalities. | 09-03-2009 |
20090252688 | Magnetic resonance contrast medium containing an iron-binding protein - An inventive principle of at least one embodiment is based on linking an iron-binding functionality in the form of a bacterial iron-binding protein to a binding element which specifically recognizes a biological structure, in order to increase a local detectable increase in the concentration of the contrast medium. In at least one embodiment of the invention, a magnetic resonance contrast medium is provided which is capable of binding by way of a binding element to a biological structure in the body of a mammal, the binding element including an isolated polypeptide. The polypeptide includes a first amino acid sequence of a bacterial iron-binding protein or a derivative thereof, wherein the bacterial iron-binding protein or said derivative thereof has an iron-binding activity. In at least one embodiment, the binding element can bind a protein. In at least one embodiment, the binding element can have a ligand for a cellular membrane protein, a ligand for a cellular glycoprotein, an antibody or an antigen-binding fragment of an antibody and/or can bind a tumor antigen. | 10-08-2009 |
20090269284 | CONTRAST AGENTS - The present invention relates generally to multimodal magnetic resonance imaging (MRI) contrast agents. In particular, the present invention provides a MRI contrast agent configured to manipulate both the longitudinal (T | 10-29-2009 |
20100021391 | NOVEL NANOPARTICLES FOR BIOFILM TARGETING - The present invention is directed to novel compositions and methods utilizing nanoparticles comprising protein cages for delivery of imaging and antimicrobial agents to biofilm forming bacterial colonies. | 01-28-2010 |
20100068151 | MULTIMODALITY MOLECULAR IMAGING WITH THERAPEUTIC CONJUGATES - Disclosed are pharmaceutical compounds comprising a cell-specific targeting moiety, an anti-cell proliferation moiety, and a chelator moiety. Also disclosed are methods for treating a subject with a hyperproliferative disease, methods for diagnosing presence of a hyperproliferative disease in a subject, and methods for detecting a therapeutic response in a subject that employ the pharmaceutical compounds of the present invention. | 03-18-2010 |
20100172843 | NANOPARTICULATE PROBE FOR IN VIVO MONITORING OF TISSUE OXYGENATION - A new class of micro- and nano-particulate paramagnetic spin probes especially useful for magnetic resonance imaging techniques, including electron paramagnetic resonance (EPR) and magnetic resonance imaging (MRI). The probes are lithium phthalocyanine derivative compounds. Also provided are suspensions and emulsions comprising lithium phthalocyanine derivative probes. Also provided are noninvasive methods for measuring noninvasive methods of measuring oxygen concentration, oxygen partial pressure, oxygen metabolism, and nitric oxide concentration in a specific tissue, organ, or cell in vivo or in vitro. | 07-08-2010 |
20100209355 | CUPREDOXIN DERIVED TRANSPORT AGENTS AND METHODS OF USE THEREOF - The present invention discloses methods and materials for delivering a cargo compound into a cancer cell. Delivery of the cargo compound is accomplished by the use of protein transduction domains derived from cupredoxins. The invention further discloses methods for treating cancer and diagnosing cancer. | 08-19-2010 |
20100233095 | CONFORMATIONALLY DYNAMIC PEPTIDES - Disclosed are novel peptides that are useful, for example, for detecting target proteins having a β-sheet secondary structure which may be associated with a disease, and for diagnosing and treating such a disease. Related methods and kits also are disclosed. | 09-16-2010 |
20100272653 | Contrast Medium for Use in Imaging Methods - An imaging auxiliary for medical imaging methods contains stabilizer-free superparamagnetic particles such as metal oxides and metals. Preferred are γ-Fe | 10-28-2010 |
20100278750 | POLYLYSINE DENDRIMER CONTRAST AGENT - The present invention relates generally to branched macromolecules and their use as imaging or contrast agents. In particular, the invention relates to dendrimers, derived from lysine or lysine analogues, bearing a plurality of functional moieties and their application to imaging techniques in which a disease state may be imaged with a targeted contrast agent. | 11-04-2010 |
20100284933 | Biomarkers of Multiple Sclerosis - Biomarkers of multiple sclerosis (MS) and of anti-TWEAK/TWEAK-Receptor therapy for MS are described. | 11-11-2010 |
20100284934 | DIAGNOSTIC AGENT - The invention provides an agent comprising an amino acid sequence for use in a method of diagnosis of a synucleinopathic disease. | 11-11-2010 |
20100284935 | MARKERS AND DIAGNOSTIC METHODS FOR METASTASIS - The present invention provides methods for the prediction, prognosis and/or diagnosis of metastasis. The present invention also provides proteins (or the related nucleic acid sequences) or protein expression profiles which are predictive and/or prognostic for metastasis. The invention thus relates to the use of said proteins and the corresponding amino acid or nucleic acid sequences for the prediction, prognosis or diagnosis of metastasis. | 11-11-2010 |
20100291001 | METALLOPROTEINASE-BINDING PROTEINS - Disclosed are antibodies that interact with a matrix metalloproteases such as MMP-26. Exemplary antibodies inhibit MMP-26 activity. These antibodies can be used, e.g., to treat or prevent metastatic disorders, hyperproliferative disorders, disorders which are characterized by excessive extracellular matrix degradation, and inflammatory disorders. | 11-18-2010 |
20110014129 | MAGNETIC MICROSTRUCTURES FOR MAGNETIC RESONANCE IMAGING - The present invention relates to a magnetic resonance structure with a cavity or a reserved space that provides contrast and the additional ability to frequency-shift the spectral signature of the NMR-susceptible nuclei such as water protons by a discrete and controllable characteristic frequency shift that is unique to each MRS design. The invention also relates to nearly uniform solid magnetic resonance T | 01-20-2011 |
20110020242 | HIGH-DENSITY LIPOPROTEIN-LIKE PEPTIDE-PHOSPHOLIPID SCAFFOLD ("HPPS") NANOPARTICLES - The present invention provides a non-naturally occurring High-Density Lipoprotein-like peptide-phospholipid scaffold (“HPPS”) nanoparticle. More particularly, the invention provides a non-naturally occurring peptide-lipid nanoscaffold comprising: (a) at least one phospholipid; (b) at least one unsaturated lipid, preferably an unsaturated sterol ester, further preferably an unsaturated cholesterol ester, further preferably cholsteryl oleate; and (c) at least one peptide, the peptide comprising an amino acid sequence capable of forming at least one amphipathic a-helix; wherein the components a), b) and c) associate to form the peptide-phospholipid nanoscaffold. In embodiments of the present invention, a cell surface receptor ligand is incorporated into the HPPS. In one embodiment, the cell surface receptor ligand is covalently bonded to the peptide scaffold of the HPPS nanoparticles. In other embodiments, a cell surface receptor ligand is coupled to a lipid anchor and is displayed on the surface of the HPPS nanoparticles by incorporation of the lipid anchor into the phospholipids monolayer of the HPPS nanoparticle. The present invention also provides pharmaceutical formulations comprising HPPS nanoparticles and methods of making the HPPS nanoparticles. | 01-27-2011 |
20110044911 | Use of Functionalized Magnetic Nanoparticles in Cancer Detection and Treatment - The present invention provides methods of detecting a cancer cell in an individual, methods of grading a cancer, and methods of treating a cancer. The methods involve use of functionalized magnetic nanoparticles that comprise a moiety that provides for selective association with, and/or metabolic uptake into, a cancer cell. | 02-24-2011 |
20110064675 | ELEMENTAL IRON NANOPARTICLES - Synthesis of iron nanoparticles with a substantially unoxidized iron core and a biocompatible coating is described. The nanoparticles are formed by reacting an iron salt solution with a reducing agent in a substantially oxygen-free environment and exposing the formed iron particles to a biocompatible coating agent in a substantially oxygen-free environment to form coated iron particles. An average diameter of the coated iron particles is between 5 nm and 25 nm. The biocompatible coating can functionalized with cell-specific agents for use as diagnostic and therapeutic agents. | 03-17-2011 |
20110097276 | Diagnosis of Prostate Cancer - Methods for diagnosing prostate cancer, and differentiate prostate cancer from other prostate complications, and use of said method, and diagnosing and monitoring lymph gland metastasis, post operative examinations, and examinations during or after radiation, cytostatic, and androgen treatments are disclosed. The methods comprise injecting tracer-labelled PSA or hK2 specific antibodies, visualising PSA or hK2 producing tissue with the aid of a visualisation method, and diagnosing prostate cancer from the difference in visualisation. | 04-28-2011 |
20110104075 | 129Xe BIOSENSORS AND THEIR USE - This invention relates to enzyme-sensitive biosensors and methods and kits using the same. Specifically, the invention relates to methods, systems and kits for the detection of enzymes using the chemical shift observed in an isotope complexed to the biosensor resulting from a change in the biosensor as the result of the enzyme's activity. | 05-05-2011 |
20110110866 | Elastin-like polypeptide and gadolinium conjugate for magnetic resonance imaging - A magnetic resonance imaging (MRI) contrast enhancement agent comprising an elastin-like polypeptide (ELP) and one or more paramagnetic metal ions is disclosed. Also disclosed are methods of preparing ELP MRI contrast enhancement agents, formulations comprising ELP MRI contrast enhancement agents, and methods of using ELP MRI contrast enhancement agents to image biological samples and to image and deliver therapeutic agents to targeted sites in vivo. In some embodiments, the ELP MRI agents can be used in methods related to blood volume determination, in magnetic resonance angiography (MRA), and in vascular transport determinations. The ELP MRI contrast agents can also provide information on the expression of various proteins through affinity targeting or enzymatic crosslinking in order to aid in diagnosis and in the spatial definition of pathologic tissue. | 05-12-2011 |
20110123457 | CONJUGATES OF 19F MR IMAGING TRACERS AND CHEMOTHERAPEUTIC AGENTS FOR DRUG QUANTIFICATION AND DRUG DOSE INDIVIDUALIZATION - A therapeutic agent formed of a magnetic resonance imaging tracer conjugated with a chemotherapeutic agent. The therapeutic agents can be used in measuring drug delivery to a target tissue. The therapeutic agents allow for therapeutic MRI, in which | 05-26-2011 |
20110250146 | MAGNETIC NANOPARTICLE AND METHOD FOR IMAGING T CELLS - The present invention provides nanoparticles having a core comprising a magnetic material and having a surface, where the surface may be operatively linked to an antigenic peptide-major histocompatibility complex (MHC) monomer. The antigenic peptide-MHC monomer may then be recognized by a T cell receptor. These nanoparticles may further comprise a signal-generating label, such as a fluorophore. Methods employing nanoparticles of the present invention may involve magnetic resonance imaging and/or fluorescence detection, such that cell imaging and localization are performed. | 10-13-2011 |
20110286935 | Multi-Functional Nano-Device - A universal drug delivery platform for monoclonal antibody-based therapeutics is described. This universal platform resolves the problems of immunogenic response associated with the present monoclonal antibody based therapeutics by providing a multifunctional nano-device which comprises a well defined core/shell nano-structure that can function as a drug delivery platform linked to a monoclonal antibody through a single linking group. | 11-24-2011 |
20110300077 | Human Anti-Alpha-Synuclein Antibodies - Provided are human alpha-synuclein-specific autoantibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for α-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for α-synuclein targeted immunotherapy and diagnosis, respectively. | 12-08-2011 |
20120020892 | FORCE-INDUCED MAGNETIZATION CONTRAST FOR DIAGNOSIS AND IMAGING - A method of detecting target molecules comprising; conjugating a first magnetic particle to a first ligand to form a first magnetic particle ligand conjugate; adding the conjugate to a sample containing target molecules to form a mixture comprising, the free conjugate and conjugate-target molecule binding pairs; measuring a first magnetization of the mixture; subjecting the mixture to a first force; measuring a second magnetization value of the mixture; subtracting the second magnetization value from the first magnetization value to calculate a first force-induced magnetization contrast; subjecting the mixture to a second force; measuring a third magnetization of the mixture; and subtracting the third magnetization value from the second magnetization value to calculate a second force-induced magnetization contrast. | 01-26-2012 |
20120087869 | METHODS FOR DISTRIBUTING AGENTS TO AREAS OF BRAIN - Broad cerebrospinal fluid (CSF) distribution of an agent is achievable by delivering the agent in a liquid formulation to the CSF at flow rates less than 500 microliters per hour, such as between about 2 microliters per hour and about 100 microliters per hour. | 04-12-2012 |
20120121517 | BIODEGRADABLE AND THERMOSENSITIVE POLY(ORGANOPHOSPHAZENE)-SUPERPARAMAGNETIC NANOPARTICLE COMPLEX, PREPARATION METHOD AND USE THEREOF - The present invention relates to a poly(organophosphazene)-superparamagnetic nanoparticle complex including a biodegradable and thermosensitive poly(organophosphazene) and a iron oxide (Fe | 05-17-2012 |
20120134931 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE - Disclosed herein, in certain embodiments, is a selective transport molecule with increased in vivo circulation. In some embodiments, a selective transport molecule disclosed herein has the formula (A-X-B-C)-M, wherein C is a cargo moiety; A is a peptide with a sequence comprising 5 to 9 consecutive acidic amino acids, wherein the amino acids are selected from: aspartates and glutamates; B is a peptide with a sequence comprising 5 to 20 consecutive basic amino acids; X is a linker; and M is a macromolecular carrier. | 05-31-2012 |
20120141380 | POLYMER NANOPARTICLES COATED BY MAGNETIC METAL OXIDE AND USES THEREOF - The invention provides nanoparticles consisting of a polymer which is a metal chelating agent coated with a magnetic metal oxide, wherein at least one active agent is covalently bound to the polymer, said nanoparticles may optionally further comprise at least one active agent physically or covalently bound to the outer surface of the magnetic metal oxide. Pharmaceutical compositions comprising these nanoparticles may be used, inter alia, for detection and treatment of tumors and inflammations. | 06-07-2012 |
20120177579 | Metal Abstraction Peptide (MAP) Tag and Associated Methods - Compositions comprising a tripeptide having the sequence XC | 07-12-2012 |
20120177580 | Metal Abstraction Peptide (MAP) Tag and Associated Methods - Compositions comprising a tripeptide having the sequence XC | 07-12-2012 |
20120183478 | Compositions, Devices, and Methods related to Prostate-Specific Membrane Antigen - PSMA ligands, compositions, and methods therefore are disclosed where the ligand is a peptide having the sequence X | 07-19-2012 |
20120258049 | POLYMALIC ACID BASED NANOCONJUGATES FOR IMAGING - Nanoconjugates that include a polymalic-based molecular scaffold with one or more imaging moiety and one or more targeting modules attached to the scaffold are provided. Methods of targeting a diseased cell or a diseased tissue in a subject by administering the nanoconjugate are described. Methods of synthesizing the nanoconjugate are also provided. | 10-11-2012 |
20120269735 | Contrast Agents and Methods for Preparing Contrast Agents - Contrast agents comprising a scaffold protein having at least one operative integrated metal ion binding site. | 10-25-2012 |
20130004431 | TRANSPORT AGENTS FOR CROSSING THE BLOOD-BRAIN BARRIER AND INTO BRAIN CANCER CELLS AND METHODS OF USE THEREOF - The present invention discloses methods and materials for delivering a cargo compound into a brain cancer cell and/or across the blood-brain barrier. Delivery of the cargo compound is accomplished by the use of protein transport peptides derived from | 01-03-2013 |
20130004432 | MONOCLONAL ANTIBODIES THAT BIND B7H6 AND USES THEREOF - Disclosed are monoclonal antibodies that specifically bind to the B7 family member B7H6, including antibodies capable of inhibiting the interaction of B7H6 with NKp30. Also disclosed are anti-B7H6 antibody-drug conjugates comprising an anti-B7H6 monoclonal antibody conjugated to a therapeutic agent. The anti-B7H6 antibodies and antibody-drug conjugates are useful in methods for exerting therapeutic effects against B7H6-expressing cells, as well as in diagnostic methods for the detection of B7H6 or B7H6-expressing cells. | 01-03-2013 |
20130011338 | CUPREDOXIN DERIVED TRANSPORT AGENTS AND METHODS OF USE THEREOF - The present invention discloses methods and materials for delivering a cargo compound into a cancer cell. Delivery of the cargo compound is accomplished by the use of protein transduction domains derived from cupredoxins. The invention further discloses methods for treating cancer and diagnosing cancer. | 01-10-2013 |
20130058873 | P97 FRAGMENTS WITH TRANSFER ACTIVITY - The present invention is related to fragments of human melanotransferrin (p97). In particular, this invention relates to treatment of diseases through the introduction of the melanotransferrin fragment conjugated to a therapeutic or diagnostic agent to a subject. | 03-07-2013 |
20130058874 | CHEMICAL EXCHANGE SATURATION TRANSFER BASED MRI USING REPORTER GENES AND MRI METHODS RELATED THERETO - Featured are a new class of reporter genes including reporter compositions as well as methods, MRI systems and MRI imaging kits related thereto. The genes according to the present invention provide MR contrast when the sample/subject is irradiated at a specific off-resonance radio-frequency (RF frequency), where the contrast mechanism utilizes chemical exchange saturation transfer (CEST) technique for imaging. | 03-07-2013 |
20130084247 | COMPOSITIONS AND METHODS TO PREVENT CANCER WITH CUPREDOXINS - The present invention discloses methods and materials for delivering a cargo compound into a cancer cell. Delivery of the cargo compound is accomplished by the use of protein transduction domains derived from cupredoxins. The cargo compound may be a nucleic acid and specifically a DNA, RNA or anti-sense. The invention further discloses methods for treating cancer and diagnosing cancer. | 04-04-2013 |
20130189189 | COMPOSITION FOR THE DIAGNOSIS, PREVENTION OR TREATMENT OF DISEASES RELATED TO CELLS EXPRESSING IL-8 OR GRO-ALPHA, COMPRISING UCB-MSCs - Provided is a gene therapy composition for transferring one of a therapeutical gene, a maker gene, or a mixture thereof to a cell that expresses interleukin-8(IL-8) or GRO-α and induces tropism of mesenchymal stem cells isolated from umbilical cord blood and/or the mesenchymal stem cells expanded from said mesenchymal stem cells (UCB-MSCs), wherein the cell-treating composition includes UCB-MSCs. Provided is a composition for treating disease related to a cell expressing IL-8 or GRO-α, that is, a brain tumor in gene therapy, by using UCB-MSCs. Provided is a composition or kit for diagnosing brain tumors, preventing brain tumors, treating brain tumors, or monitoring brain tumor treatment progression by using UCB-MSCs. | 07-25-2013 |
20130243700 | Proteomic Antisense Molecular Shield and Targeting - The present invention provides compositions and methods for shielding and directing agents to biological targets in cellular systems for therapeutic, prophylactic, and diagnostic uses. Vascular devices are also provided which have coated surfaces that contain proteomic antisense, as well as therapeutic and other biological agents attached thereto. | 09-19-2013 |
20130280173 | REPORTER GENES FOR MAGENTIC RESONANCE IMAGING AND METHODS OF USE THEREOF - The invention provides a fusion ferritin protein wherein a ferritin heavy chain polypeptide is fused to a peptide, wherein the peptide is fused to the C-terminal end of the ferritin heavy chain; and the peptide includes at least a portion of a Mms6 protein sequence and at least one heterologous amino acid at its N-terminal end. The invention further provides methods of use of the ferritin fusion protein for Magnetic Resonance Imaging. | 10-24-2013 |
20130309177 | In Vivo Copper-Free Click Chemistry for Delivery of Therapeutic and/or Diagnostic Agents - The present application discloses compositions and methods of synthesis and use involving click chemistry reactions for in vivo or in vitro formation of therapeutic and/or diagnostic complexes. Preferably, the diagnostic complex is of use for | 11-21-2013 |
20130315840 | COMPOUND - A compound including a polymer is represented by general formula (1): | 11-28-2013 |
20140037554 | CUPREDOXIN DERIVED TRANSPORT AGENTS AND METHODS OF USE THEREOF - The present invention discloses methods and materials for delivering a cargo compound into a cancer cell. Delivery of the cargo compound is accomplished by the use of protein transduction domains derived from cupredoxins. The invention further discloses methods for treating cancer and diagnosing cancer. | 02-06-2014 |
20140056820 | TRANSPORT AGENTS FOR CROSSING THE BLOOD-BRAIN AND INTO BRAIN CANCER CELLS AND METHODS OF USE THEREOF - The present invention discloses methods and materials for delivering a cargo compound into a brain cancer cell and/or across the blood-brain barrier. Delivery of the cargo compound is accomplished by the use of protein transport peptides derived from | 02-27-2014 |
20140105827 | METHOD OF SCREENING FOR COLON CANCER USING BIOMARKERS - The present invention relates to biomarkers for colon cancers, specifically adenomas and adenocarcinomas in the GI tract. The inventors have discovered that the expression and/or overexpression of biomarkers such as CLDN1, GPR56, GRM8, LY6G6D, TLR4 and SLCO1B3 are indicative of adenomas and adenocarcinomas. A method of detecting colon cancer using targeted molecular imaging agents is also presented. | 04-17-2014 |
20140112872 | MAGNETIC RELAXOMETRY USING MAGNETIZATION AND MEASUREMENT FIELDS - The present invention provides methods and apparatuses for detecting, measuring, or locating cells or substances present in even very low concentrations in vivo in subjects, using targeted magnetic nanoparticles and special magnetic systems. The magnetic systems can comprise magnetizing subsystems and sensors subsystems, including as examples SQUID sensors and atomic magnetometers. The magnetic systems can detect, measure, or location particles bound by antibodies to cells or substances of predetermined types. Example magnetic systems are capable of detecting sub-nanogram amounts of these nanoparticles. | 04-24-2014 |
20140140933 | ANTI-COMPLEMENT C1S ANTIBODIES AND USES THEREOF - The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions. | 05-22-2014 |
20150071861 | POLYMER, CONTRAST AGENT FOR NUCLEAR MAGNETIC RESONANCE ANALYSIS OR MAGNETIC RESONANCE IMAGING USING THE POLYMER, COMPOUND AND METHOD OF NUCLEAR MAGNETIC RESONANCE ANALYSIS AND METHOD OF MAGNETIC RESONANCE IMAGING USING THE POLYMER - As a substance used as a contrast agent for a method of nuclear magnetic resonance analysis or a method of magnetic resonance imaging, a substance with high selectivity and high sensitivity was demanded. According to the present invention, when a polymer having, in a side chain thereof, a sequence of a | 03-12-2015 |
20150110721 | Modulation of a Response Signal to Distinguish Between Analyte and Background Signals - A method for modulating a response signal includes introducing functionalized particles into a lumen of subsurface vasculature, wherein the functionalized particles are configured to interact with one or more target analytes present in blood circulating in the subsurface vasculature; and non-invasively detecting the one or more target analytes. A response signal, which may include a background signal and an analyte response signal related to interaction of the functionalized particles with the one or more target analytes, is transmitted from the subsurface vasculature. A modulation configured to alter the response signal such that the analyte response signal is affected differently than the background signal may be applied to a portion of subsurface vasculature. Analyte detection may be achieved by differentiating the analyte response signal from the background signal. | 04-23-2015 |
20150147278 | ANTIBODY AGAINST TRANSPORTER AND USE THEREOF - The present invention provides a prophylactic or therapeutic agent for various malignant tumors, including currently intractable solid tumors, which contains a novel antibody having the ability to bind to human LAT1/CD98 and inducing antibody-dependent cellular cytotoxicity specifically against cancer cells as an active ingredient. | 05-28-2015 |
20160031947 | CUPREDOXIN DERIVED TRANSPORT AGENTS AND METHODS OF USE THEREOF - The present invention discloses methods and materials for delivering a cargo compound into a cancer cell. Delivery of the cargo compound is accomplished by the use of protein transduction domains derived from cupredoxins. The invention further discloses methods for treating cancer and diagnosing cancer. | 02-04-2016 |
20160058893 | MICROPARTICLE COMPOSITIONS - There is provided a microparticle composition suitable for molecular imaging, the composition comprising microparticles, wherein the microparticles comprise: a core microparticle structure having a central area and a shell, and wherein the core microparticle structure comprises (i) a phosphatidylcholine lipid: (ii) a phosphatidylethanolamine lipid comprising at least one maleimide moiety; and (iii) an alkoxylated fatty acid. | 03-03-2016 |
20160136308 | METHODS AND APPARATUSES FOR THE LOCALIZATION AND TREATMENT OF DISEASE SUCH AS CANCER - Embodiments of the present invention provide methods of detecting disease, methods of treating disease using targeted hyperthermia, methods of treating disease using targeted chemical agents, methods of treating disease comprising accurate measurements of the efficacy of treatments. The effect of nanoparticles on magnetic fields can be used to determine the location of a disease, and a measure of the number of cells characteristic of the disease. This location and measure can be used to guide therapy, and provide information regarding the most effective therapy to be applied. The same nanoparticles can be used to facilitate hyperthermia treatments, and to allow targeted application of chemical therapeutic agents. | 05-19-2016 |
20160168225 | EXENDIN-4 PEPTIDE ANALOGUES AS DUAL GLP-1/GLUCAGON RECEPTOR AGONISTS | 06-16-2016 |
20160176852 | CYANINE COMPOUNDS | 06-23-2016 |
20160184463 | LABELED LIGANDS OF ANTI-MULLERIAN HORMONE FOR DIAGNOSIS OF ENDOMETRIOSIS - The present invention relates to isolated ligands of anti-Mullerian hormone marked so as to be directly detectable by means of magnetic resonance imaging in the endometriosic lesions. In particular, such ligands can be used in a method for diagnosing in vivo endometriosis wherein said method comprises a passage of localizing and/or evaluating the entity of the endometriosic lesions in a patient. | 06-30-2016 |
20160193369 | MAGNETIC NANOPARTICLE AND METHOD FOR IMAGING T CELLS | 07-07-2016 |
20160375155 | Collagen Imaging Compositions - Compounds and methods for imaging and/or assessing collagen are described. The compounds can include collagen binding peptides. | 12-29-2016 |
424900341 | The region of the imaging agent responsible for binding to an in vivo target or the region of the target responsible for binding to the agent is specifically recited functionally or as a sequence of amino acids, carbohydrate residues, or nucleic acids | 13 |
20080206152 | In Vivo Expression Profiling - The present invention relates to in vivo expression profiling using a plurality of specific targeting moieties each labelled with a different compound which allows to identify simultaneously the binding of each targeting moiety to a target. | 08-28-2008 |
20100303733 | Systems, devices, methods, and compositions including ferromagnetic structures - Magnetic resonance systems, devices, methods, and compositions are provided. A nuclear magnetic resonance imaging composition includes, but is not limited to, a plurality of ferromagnetic microstructures configured to generate a time-invariant magnetic field within at least a portion of one or more internal surface-defined voids. In an embodiment, at least one of the plurality of ferromagnetic microstructures includes one or more targeting moieties attached thereof. | 12-02-2010 |
20120093733 | MULTIDOMAIN BIOTAGS FOR CANCER DETECTION, DIAGNOSIS AND THERAPY AND METHODS OF THEIR USE - In one embodiment, a biotag for targeting a cancer biomarker is provided. The biotag may include a cancer biomarker binding domain, an internalization domain, an endosomal escape domain, a lysosomal escape domain, a reporter binding domain, and a reporter, wherein the reporter is a diagnostic agent. In some aspects, the cancer biomarker is ERBB 1-4, EGFRvIII or Transferrin Receptor (TfR). In other aspects, the binding domain is an scFv, an sdFv, a CDR or an SDR modified CDR. In some aspects, the reporter binding domain is a metal binding domain, which may be chelated to a metal nanoparticle tag. In some aspects, the metal nanoparticle tag is a noble metal, a superparamagnetic metal, a core-shell nanoparticle, or a fluorescent agent. In another embodiment, a targeted contrast composition for use with a diagnostic imaging technique is provided, which includes a contrast agent and a biotag for targeting a cancer biomarker. | 04-19-2012 |
20120093734 | PROTEIN-BASED METHODS AND COMPOSITIONS FOR THE DIAGNOSIS OF COLORECTAL ADENOCARCINOMA - Protein-based methods and compositions for the diagnosis of colorectal adenocarcinoma are disclosed. A method for identifying cell-surface proteins, which are transmembrane proteins or proteins with a signal peptide and which are over-expressed in colorectal cancer (CRC) is disclosed. Biomarkers found with this method, diagnostic methods using them and contrast agents directed to them for use in magnetic resonance imaging (MRI) and/or magentic photon imaging (MPI) are disclosed. The methods and biomarkers allow for differentiating progressive (high-risk) CRC (adenocarcinomas) from non-progressive (low-risk) colorectal adenomas. | 04-19-2012 |
20120114565 | COMPOUNDS MODULATORS OF VEGF ACTIVITY AND USES THEREOF - Compounds of general formula (1): X1Y1X2Y2X3Y3X4Y4Y5X5X6Y6X7Y7X8X9X10 wherein X1-X10 are any natural or unnatural amino acids and Y1 is Gln; Y2 is Met or Leu; Y3 is He; Y4 is Pro or Ser; Y5 is His or Gly; Y6 is Gln or Pro; Y7 is He or Tyr or their homolog or ortolog are described; these compounds are able to bind to the VEGF receptors and to modulate the angiogenesis mediated by the VEG. | 05-10-2012 |
20120244080 | PROTEIN AGENT FOR DIABETES TREATMENT AND BETA CELL IMAGING - Glucagon-like peptide-1 (GLP-1) is a member of a large family of incretin hormones secreted in nutrient-dependent response. GLP-1 acts on GLP-1 receptor (GLP-1 R) that is highly expressed on pancreatic β-cells. The peptide has great potential for development of diabetes treatment and diagnosis. However, the pharmaceutical effects of the peptide suffer from in vivo instability and short life due to degradation by Dipeptidylpeptidase-1 (DPP-4). The 30 amino acid peptide GLP-1 has been integrated into a stable host protein human calbindin D9k. The fusion protein binds to GLP-1 R as demonstrated by immunostaining analyses of GLP-1 R expressing cells. The fusion protein agents can be useful for both diabetes treatment and GLP-1 R receptor targeting MR imaging. The fusion protein has a size about 14 kDa, which enables efficient tissue penetration and retention, and an extended circulation time, is stable, remaining intact and retaining activity after 48 hours incubation with 75% human serum. The protein retains its native folded structure after boiling for ten minutes forming the basis of an experimental protocol for large scale production of the fusion protein (>30 mg/l bacterial culture). No toxicity has been observed with tests on mice. One aspect of the disclosure, therefore, provides a fusion protein comprising a first peptide characterized by selectively binding to a site of a target cell and linked to a second peptide, where the fusion protein is more stable than the first peptide alone. In embodiments of this aspect of the disclosure, the fusion protein may further comprise a detectable label attached thereto. In some embodiments of this aspect of the disclosure, the first peptide of the fusion protein may be glucagon-like peptide-1 (GLP-1), glucagon-like peptide-1 (GLP-1)(7-36), or glucagon-like peptide-1 (GLP-1) (9-36), or a conservative variant thereof. | 09-27-2012 |
20130251642 | CHIMERIC RABBIT/HUMAN ROR1 ANTIBODIES - The invention relates to antibodies having specificity for human ROR1, compositions thereof, and methods for using such antibodies, including in the diagnosis and treatment of disorders associated with aberrant ROR1 expression. | 09-26-2013 |
20130295021 | HUMAN ANTI-TAU ANTIBODIES - Provided are human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively. | 11-07-2013 |
20140127139 | COMPOUNDS FOR DIAGNOSING DISEASES ASSOCIATED WITH THE EXPRESSION OF MUC5AC - The application relates to a compound of general formula (I) below: | 05-08-2014 |
20140341814 | COMPOUNDS MODULATORS OF VEGF ACTIVITY AND USES THEREOF - Compounds of general formula (1): X1Y1X2Y2X3Y3X4Y4Y5X5X6Y6X7Y7X8X9X10 wherein X1-X10 are any natural or unnatural amino acids and Y1 is Gln; Y2 is Met or Leu; Y3 is He; Y4 is Pro or Ser; Y5 is His or Gly; Y6 is Gln or Pro; Y7 is He or Tyr or their homolog or ortolog are described; these compounds are able to bind to the VEGF receptors and to modulate the angiogenesis mediated by the VEG. | 11-20-2014 |
20140369940 | Anti-Alpha Synuclein Binding Molecules - Provided are anti-human α-synuclein-specific binding molecules, e.g., antibodies or antigen-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human α-synuclein binding molecules which bind to specific N-terminal and C-terminal epitopes on human α-synuclein. The binding molecules described herein can be used in pharmaceutical and diagnostic compositions for α-synuclein targeted immunotherapy and diagnosis, respectively. | 12-18-2014 |
20150093336 | ANTI-MACROPHAGE MANNOSE RECEPTOR SINGLE VARIABLE DOMAINS FOR TARGETING AND IN VIVO IMAGING OF TUMOR-ASSOCIATED MACROPHAGES - The disclosure relates to immunoglobulin single variable domains directed against human macrophage mannose receptor (MMR) and their uses in the field of oncology. More specifically, it concerns immunoglobulin single variable domains, including single-domain antibodies (sdAbs), against human MMR and their use in targeting and in vivo imaging of tumor-associated macrophages, with applications in the field of cancer diagnostics and therapeutics and monitoring of the disease. | 04-02-2015 |
20160250356 | TARGETED CONTRAST AGENTS AND METHODS FOR TARGETING CONTRAST AGENTS | 09-01-2016 |